Skip to main content

Table 2 Change in HDL-c in breast cancer patients on DOX treatment

From: Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?

Study Sample Chemotherapy regimen and duration Results
[144] N = 1054
breast cancer patients
TAC (n = 251)
Cycled every 21 days for 6 cycles
CEF (n = 9)
Cycled every 21 days for 6 cycles
AC-T (n = 134)
AC cycled every 21 days for 6 cycles followed by T cycled every 21 days for 4 cycles
HDL-c prechemotherapy vs. post chemotherapy
[152] N = 12
breast cancer patients
AC-P (n = 7)
AC 3 times weekly for 4 weeks followed by P once weekly for 12 weeks
CEF-T (n = 5)
3 times weekly for 3 weeks followed by T 3 times weekly for 3 weeks
HDL-c prechemotherapy vs. post chemotherapy
  1. A Doxorubicin, C Cyclophosphamide, E Epirubicin, F 5-Flouracil, T Docetaxel, P Paclitaxel, vs. Versus